NEUROSTAR TMS THERAPY SYSTEM 81-60000-000

MAUDE Adverse Event Report

MAUDE data represents reports of adverse events involving medical devices. This maude entry was filed from a 05 report with the FDA on 2012-09-20 for NEUROSTAR TMS THERAPY SYSTEM 81-60000-000 manufactured by Neuronetics, Inc..

Event Text Entries

[15508228] The pt is a (b)(6) man with mdd who had been receiving tms over the l-dlpc with stimulation parameters noted below. He noticed left eye floaters suddenly on (b)(6), just after tms session #26 on the left side. He saw an ophthalmologist on (b)(6). The ophthalmology exam revealed a new posterior vitreous detachment (pvd) on the left and an old vitreous detachment on the right. There was no retinal holes or tears. The ophthalmologist impression was that the pvd was unrelated to the tms. The pt had a single tms session on the right dorsolateral pfc on (b)(6). The ophthalmologist cleared pt to resume left-sided tms on (b)(6). After the 1st ophthalmologist visit, the tms treating physician specifically looked for eye movements or lid twitching during the tms treatments and asked the pt if he noted any visual change during the treatment session but neither he nor pt noted any movements. A second wave of acute floaters developed on (b)(6), after tms session # 35. He saw the ophthalmologist that afternoon who identified a new left retinal detachment which responded to laser treatment. The laser treatment has been holding well since (b)(6). The pt has made a good recovery of his visual function.
Patient Sequence No: 1, Text Type: D, B5


[15751594] Treatment parameters - motor threshold: 0. 85. Treatment protocol: dlpfc at 20hz, 80% mt, 2 sec/28 sec x 1000 pulses followed by left dlfpc 20 hz at 119% mt, 2 sec on, 28 sec off, for 2400 pulses. These parameters differ from the treatment parameters specified in the neurostar tms therapy system user manual (10hz, 120%mt, 4 sec on/26 sec off, 300 pulses). After the initial visit to the ophthalmologist the treating physician and the ophthalmologist assessed the posterior vitreous detachment (pvd) as not tms related, but after the second ophthalmologist visit for the retinal tear, they assessed the retinal tear as tms related. The neuronetics assessment of the causality is that the pvd was not tms related, with risk factors of treated hypertension, diabetes, and evidence of prior pvd in the contralateral eye. The retinal tear is possibly tms related given the timing in relation to the tms treatment, but is still confounded by the risk factors mentioned above. The device service records were obtained and reviewed. Results of this found that the device was functioning as intended and there were no significant or atypical services performed to the subject device that would have an affect on or cause the medical event.
Patient Sequence No: 1, Text Type: N, H10


MAUDE Entry Details

Report Number3004824012-2012-00002
MDR Report Key2757435
Report Source05
Date Received2012-09-20
Date of Report2012-09-20
Date of Event2012-08-17
Date Mfgr Received2012-08-23
Device Manufacturer Date2010-04-01
Date Added to Maude2012-09-26
Event Key0
Report Source CodeManufacturer report
Manufacturer LinkY
Number of Patients in Event0
Adverse Event Flag3
Product Problem Flag3
Reprocessed and Reused Flag3
Health Professional3
Initial Report to FDA3
Report to FDA0
Event Location0
Manufacturer ContactDR. JUDY WAYS, PHD
Manufacturer Street31 GENERAL WARREN BLVD
Manufacturer CityMALVERN PA 19355
Manufacturer CountryUS
Manufacturer Postal19355
Manufacturer Phone6109814107
Single Use3
Previous Use Code3
Event Type3
Type of Report3

Device Details

Brand NameNEUROSTAR TMS THERAPY SYSTEM
Generic NameTRANSCRANIAL MAGNETIC STIMULATOR
Product CodeOBP
Date Received2012-09-20
Model Number81-60000-000
OperatorHEALTH PROFESSIONAL
Device AvailabilityY
Device Eval'ed by MfgrN
Device Sequence No1
Device Event Key0
ManufacturerNEURONETICS, INC.
Manufacturer Address31 GENERAL WARREN BLVD MALVERN PA 19355 US 19355


Patients

Patient NumberTreatmentOutcomeDate
101. Required No Informationntervention 2012-09-20

© 2024 FDA.report
This site is not affiliated with or endorsed by the FDA.